Browse by author
Lookup NU author(s): Professor Anthony MoormanORCiD, Claire Schwab, Emily Winterman, Dr Frederik van DelftORCiD, Professor Christine Harrison FRCPath FMedSci
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons LtdPatients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
Author(s): Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A
Publication type: Article
Publication status: Published
Journal: British Journal of Haematology
Year: 2020
Volume: 191
Issue: 5
Pages: 844-851
Print publication date: 01/12/2020
Online publication date: 14/09/2020
Acceptance date: 17/08/2020
Date deposited: 06/01/2021
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141
Publisher: Blackwell Publishing Ltd
URL: https://doi.org/10.1111/bjh.17093
DOI: 10.1111/bjh.17093
Altmetrics provided by Altmetric
